Share |
News

Verisante Announces Exclusive Distribution Agreement with Laserwelt Berlin for Germany, Austria and Liechtenstein


January 10, 2013 at 2:00 pm

SKIN CANCER INCIDENCE IN GERMANY IS 20 PER CENT HIGHER 
THAN THE REST OF EUROPE

VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt: V3T) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that the Company has entered into an exclusive agreement with Laserwelt to distribute Verisante Aura™ in Germany, Austria and Liechtenstein. 

“Laserwelt is one of the most successful independent distributors of medical devices in German- speaking countries,” said Thomas Braun, President & CEO of Verisante. “Germany is one of the largest markets in Europe for dermatological and skin care devices. Our partnership with Laserwelt will provide a strong foundation in this important region. Laserwelt will distribute Aura™ and also support technical training and servicing in Germany, Austria and Liechtenstein.”

Laserwelt has a showroom in downtown Berlin and currently distributes the world’s top dermatological brands of medical devices for skin care treatments, in addition to other devices for use in dermatological practices for a variety of other medical applications. Aura™ is a complementary addition to the Company’s existing product line.

“Germany is the only country in the world that has a national skin cancer screening program for persons over 35 years of age,” said Michael Landsberg, Owner and President of Laserwelt. “Given that Aura’s™ clinical study results show the device can quickly and accurately assist in skin cancer diagnosis, we are confident of widespread market adoption.”

The European medical device market is the second largest in the world, worth over $78 billion and representing 30 per cent of the world market – second only to the United States. Last year, Aura™ received the Conformite Europeenne (CE) Mark approval. CE Mark is recognized by all the 27 Member States of the EU, including Germany, which has a total population of over 81 million people, and over 5,000 dermatologists serving the country.

In Germany the incidence of skin cancers has tripled since 1980 and is about 20 per cent higher than the rest of Europe, with melanoma accounting for 2,217 deaths each year. Germany also offers a reimbursement under their state health insurance which covers skin cancer screenings every two years for people age 35 and older.

Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.

About Laserwelt

Laserwelt is a medical device distributor of innovative high technology solutions for professionals in dermatology, founded in Germany with head office in Berlin. Laserwelt´s owner, Michael Landsberg, has won several university clinics in German-speaking countries as costumers and key opinion leaders. Laserwelt Berlin is highly successful with its “nothing missing” portfolio, unbeatable service and professional live education for doctors, with 20 years of experience in the dermatology field. Laserwelt has over 92,000 likes on Facebook. Laserwelt offers highly professional, modern and comprehensive marketing both on- and offline to assure the fastest possible break-even point for their costumers.

For more information on Laserwelt, visit the Company’s website at http://www.laserwelt.com

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.

Verisante Aura™ was awarded Popular Science Magazine’s “Best of What’s New Award” for 2011, and Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. In addition, the Company was named the year’s top ranking Technology and Life Sciences Company on the TSX Venture 50.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Company Contact:
                       
Thomas Braun, President & CEO                   
Verisante Technology, Inc.                   
Telephone: (604) 605-0507                   
Email: info@verisante.com                   
Website:  www.verisante.com                     
Youtube:  www.youtube.com/verisante                 
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top